TMCnet News
AGTC to Present at Phacilitate Cell & Gene Therapy World 2017GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 12, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced its participation in the upcoming Phacilitate Cell & Gene Therapy World 2017 conference, taking place in Miami, Florida from January 17-20, 2017. AGTC President & CEO Sue Washer will deliver a presentation entitled “Tools and endpoints for evaluating vision in retinal disease clinical trials," on Friday, January 20th at 12:55 PM – 1:20 PM EST as part of the conference’s “Therapeutic Area Clinical Update: CNS & Ophthalmology” section. She will discuss AGTC’s two ongoing gene therapy clinical trials, the range of ophthalmology clinical endpoints and how they are measured, how they define and describe the patient visual experience, and how results in AGTC's clinical development programs could be reported. Information for physicians, patients and families seeking details about AGTC’s currently enrolling clinical trials for X-linked retinoschisis (XLRS) and achromatopsia (ACHM) is available t www.agtc.com/patients-and-caregivers. About AGTC AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products. IR/PR CONTACTS: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 [email protected] or [email protected] Corporate Contacts: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 [email protected] Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected] |